| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | W Egner | |
| P2860 | cites work | The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus | Q68283327 |
| Isotypic distribution of anti-double-stranded DNA antibodies: a diagnostic evaluation by enzyme-linked immunosorbent assay | Q68323441 | ||
| Cross-reactivity distinguishes serum and nephritogenic anti-DNA antibodies in human lupus from their natural counterparts in normal serum | Q68785743 | ||
| Congenital complete heart block. A human model of passively acquired autoimmune injury | Q68800355 | ||
| Clinical significance of IgG anti-Sm antibodies in patients with systemic lupus erythematosus | Q68804365 | ||
| C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus | Q68825041 | ||
| IgM anti-histone H-3 antibody associated with undifferentiated rheumatic disease syndromes | Q68954325 | ||
| Antihistone antibodies in systemic lupus erythematosus | Q68999789 | ||
| Anti-(U1)RNP and anti-Sm autoantibody profiles in patients with systemic rheumatic diseases: differential detection of immunoglobulin G and M by immunoblotting | Q69566987 | ||
| Serum C4 concentration in the monitoring of systemic lupus erythematosus: requirement for C4 allotyping | Q69601687 | ||
| The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus | Q69772744 | ||
| Quantitation of anti-RNP and anti-Sm antibodies in MCTD and SLE patients by immunoblotting | Q69885859 | ||
| Clinical significance of anti-nDNA antibodies in ANA-positive systemic lupus erythematosus: comparison of the Farr radioimmunoassay and the Crithidia luciliae immunofluorescent technique | Q69904027 | ||
| Assays for Sm and RNP antibodies: pitfalls and technical considerations | Q69945695 | ||
| Specificity of the Crithidia luciliae method for detecting anti-DNA antibodies. Effect of absorption for lipoproteins | Q70101161 | ||
| A solid-phase radioimmunoassay for anti-histone antibodies in human sera: comparison with an immunofluorescence assay | Q70227952 | ||
| Clinical profiles of patients with antibodies to nuclear ribonucleoprotein | Q70232740 | ||
| Anti-double-stranded DNA antibodies in the healthy elderly: prevalence and characteristics | Q70261518 | ||
| C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study | Q70261715 | ||
| Autoantibodies directed against sicca syndrome antigens in the neonatal lupus syndrome | Q70659196 | ||
| Clinical evaluation of various selected ELISA kits for the detection of anti-DNA antibodies | Q70905179 | ||
| Enzyme-linked immunosorbent assay for anti-histone antibodies and their presence in systemic lupus erythematosus sera | Q70912861 | ||
| Small changes in outpatients lupus activity are better detected by clinical instruments than by laboratory tests | Q70988673 | ||
| Incidence and clinical significance of anti-ENA antibodies in systemic lupus erythematosus. Estimation by counterimmunoelectrophoresis | Q71007155 | ||
| The significance of anticardiolipin antibodies in patients with lupus nephritis | Q71115749 | ||
| Detection of antibodies to DNA: a technical assessment | Q67471260 | ||
| The Clinical Significance of Measuring Different Anti-dsDNA Antibodies by Using the Farr Assay, an Enzyme Immunoassay and a Crithidia luciliae Immunofluorescence Test | Q67483556 | ||
| Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement | Q67569108 | ||
| Changes in levels of antibodies against the 70 kDa and a polypeptides of the U1RNP complex in relation to exacerbations of systemic lupus erythematosus | Q67901205 | ||
| Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study | Q67925068 | ||
| Detection and occurrence of the 60- and 52-kD Ro (SS-A) antigens and of autoantibodies against these proteins | Q68004801 | ||
| Clinical relevance of the estimation of antibodies to single stranded DNA in systemic lupus erythematosus | Q68098087 | ||
| Diagnosis of systemic lupus erythematosus in Jamaica by Crithidia luciliae indirect immunofluorescence test | Q68177089 | ||
| Low avidity antibodies to dsDNA as a diagnostic tool | Q24514784 | ||
| Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus | Q28290536 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis | Q30449890 | ||
| The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases | Q33498243 | ||
| Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests | Q33502230 | ||
| Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus | Q33552323 | ||
| Prognostic value of anti-dsDNA in SLE | Q33553757 | ||
| Serum C-reactive protein measurement in the detection of intercurrent infection in Oriental patients with systemic lupus erythematosus | Q33555821 | ||
| Evaluation of an ELISA system for determination of class-specific antibodies to native and denatured DNA in man. | Q33556017 | ||
| Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus | Q33556592 | ||
| Measurement of anti-DNA antibodies: a reappraisal using five different methods | Q33557485 | ||
| Specificity of anti-Sm antibodies by ELISA for systemic lupus erythematosus: increased sensitivity of detection using purified peptide antigens | Q33561148 | ||
| Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively | Q33561747 | ||
| Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus | Q33562546 | ||
| Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome? | Q33566129 | ||
| Range of antinuclear antibodies in "healthy" individuals | Q34065272 | ||
| The Occurrence of Single-Stranded DNA in the Serum of Patients with Systemic Lupus Erythematosus and Other Diseases | Q34215374 | ||
| Antibodies to native DNA and serum complement (C3) levels. Application to diagnosis and classification of systemic lupus erythematosus | Q34264172 | ||
| Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays | Q34441511 | ||
| Implications of anti-Ro/Sjögren's syndrome A antigen autoantibody in normal sera for autoimmunity | Q34564413 | ||
| Detection of autoantibodies in a quantitative immunoassay using recombinant ribonucleoprotein antigens | Q35290633 | ||
| Anti-Ro/SS-A and anti-La/SS-B antibodies associated with cardiac involvement in childhood systemic lupus erythematosus | Q35547207 | ||
| The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases | Q37342793 | ||
| Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease | Q37950614 | ||
| The measurement of anti-DNA activity in the sera of patients with systemic lupus erythematosus: theoretical and practical considerations | Q38219271 | ||
| Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique | Q38360359 | ||
| Serial studies of the IgG subclass and functional affinity of DNA antibodies in systemic lupus erythematosus | Q38971416 | ||
| Lack of specificity for antibodies to double stranded DNA found in four commercial kits | Q39462181 | ||
| Seronegative systemic lupus erythematosus | Q39582216 | ||
| Utility of anti-Sm, anti-RNP, anti-Ro/SS-A, and anti-La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus | Q71127080 | ||
| Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity | Q71160332 | ||
| Predominance of IgM anti-U1RNP antibodies in patients with systemic lupus erythematosus | Q71160651 | ||
| Levels of lupus autoantibodies in pregnant SLE patients: correlations with disease activity and pregnancy outcome | Q71538129 | ||
| Development of the anti-Ro autoantibody response in a patient with systemic lupus erythematosus | Q71620527 | ||
| Serum complement determinations in patients with quiescent systemic lupus erythematosus | Q71906026 | ||
| Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests | Q71933430 | ||
| Anti-double stranded DNA, anti-histone, and anti-nucleosome IgG reactivities in children with systemic lupus erythematosus | Q72079248 | ||
| Correlation and predictive accuracy of circulating immune complexes with disease activity in patients with systemic lupus erythematosus | Q72129326 | ||
| Evaluation of recombinant Ro/SSA, La/SSB, Sm, and U1 RNP autoantigens in clinical diagnosis | Q72170499 | ||
| Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significance | Q72231867 | ||
| Development of anti-Sm and anti-DNA antibodies followed by clinical manifestation of systemic lupus erythematosus in an elderly woman with long-standing Sjögren's syndrome | Q72279365 | ||
| Prevention of relapses in systemic lupus erythematosus | Q72318708 | ||
| Anti-La/SSB antibody is present in some normal sera and is coincident with anti-Ro/SSA precipitins in systemic lupus erythematosus | Q72736551 | ||
| Anticardiolipin antibodies in systemic lupus erythematosus: clinical correlates, HLA associations, and impact on survival | Q72742682 | ||
| IgM and IgG subclass distribution of human anti-Ro/SSA 60 kDa autoantibodies | Q72745316 | ||
| Clinical course of patients with anti-RNP antibodies | Q72922733 | ||
| Laboratory tests as predictors of flares in systemic lupus erythematosus: comment on the article by Esdaile et al | Q73092687 | ||
| Production of anti-Ro/SS-A and anti-La/SS-B autoantibodies is closely coordinated in systemic lupus erythematosus and independent of anti-dsDNA production | Q73175691 | ||
| Anti beta 2glycoprotein I antibodies and lupus anticoagulant in patients with recurrent pregnancy loss: prevalence and clinical significance | Q73262337 | ||
| Are antibodies to ribosomal P proteins a clinically useful predictor of neuropsychiatric manifestations in patients with systemic lupus erythematosus? | Q73262394 | ||
| Systemic lupus erythematosus: clinical expression and anti-Ro/SS--a response in patients with and without lesions of subacute cutaneous lupus erythematosus | Q73262407 | ||
| Serial analysis of autoantibody responses to the collagen-like region of Clq, collagen type II, and double stranded DNA in patients with systemic lupus erythematosus | Q73337096 | ||
| Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation | Q73418232 | ||
| Prevalence and disease associations of certain autoantibodies in elderly patients | Q74345970 | ||
| The sensitivity and specificity of autoantibodies to the Sm antigen in the diagnosis of systemic lupus erythematosus | Q74551013 | ||
| Antibodies to nRNP, Sm, Ro(SSA) and La(SSB) detected by ELISA: their specificity and inter-relations in connective tissue disease sera | Q93670700 | ||
| Significance of serum c-reactive protein elevation in patients with systemic lupus erythematosus | Q39638467 | ||
| Avidity of antibodies in SLE: relation to severity of renal involvement | Q39802398 | ||
| U1RNP positive neonatal lupus erythematosus: association with anti-La antibodies? | Q40524512 | ||
| Serological markers of disease activity in systemic lupus erythematosus | Q40552933 | ||
| Anti-dsdna and complement profiles as prognostic guides in systemic lupus erythematosus | Q40703151 | ||
| Complement-fixing anti--double-stranded DNA with the Crithidia method: a better indicator of active SLE than anti-DNA with the Farr method | Q40980849 | ||
| Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study | Q41192552 | ||
| Antibodies to native DNA in connective tissue disease. A comparison of radioimmunoassay, counterimmunoelectrophoresis and indirect immunofluorescence on Crithidia luciliae substrate | Q41193393 | ||
| Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? | Q41219723 | ||
| Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology | Q41258120 | ||
| Significance of Levels of Specific Immunoglobulins to DNA in SLE Patients' Sera Detected by Solid Phase Radioimmunoassay | Q41453736 | ||
| Antibodies to DNA. | Q41756806 | ||
| Changes in anti-U1 RNA antibody levels correlate with disease activity in patients with systemic lupus erythematosus overlap syndrome | Q41813807 | ||
| Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population | Q42037849 | ||
| Antibody reactivity against single stranded DNA of various species in normal children and in children with diffuse connective tissue diseases | Q42630665 | ||
| A prospective study on anti-endothelial cell antibodies in patients with systemic lupus erythematosus | Q43490054 | ||
| IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus | Q43804421 | ||
| Restricted epitope recognition by precipitin-negative anti-La/SS-B-positive sera | Q43894230 | ||
| The diagnostic associations of patients with antinuclear antibodies referred to a community rheumatologist | Q44088706 | ||
| Evaluation of commercial enzyme immunoassays compared to immunofluorescence and double diffusion for autoantibodies associated with autoimmune diseases | Q44165619 | ||
| Serological detection of disease activity in SLE | Q44168826 | ||
| Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease | Q44532633 | ||
| Effectiveness of testing for anti-DNA and the complement components iC3b, Bb, and C4 in the assessment of activity of systemic lupus erythematosus | Q44556823 | ||
| Soluble interleukin-2 receptors in systemic lupus erythematosus | Q44557817 | ||
| Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations | Q46152455 | ||
| Role of antiribosomal P protein antibodies in the diagnosis of lupus isolated to the central nervous system | Q46278780 | ||
| The relationship of anticardiolipin antibodies to disease activity in systemic lupus erythematosus | Q46577397 | ||
| Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations | Q46597454 | ||
| Long-term follow-up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients | Q47801642 | ||
| Association of anti-Sm antibodies with organic brain syndrome secondary to systemic lupus erythematosus | Q48154772 | ||
| Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus | Q48934171 | ||
| Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. | Q49114680 | ||
| The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus | Q49236690 | ||
| Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. | Q51011401 | ||
| Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. | Q51033273 | ||
| Increased anti-Sm antibodies in schizophrenic patients and their families. | Q52033703 | ||
| A longitudinal study of circulating immune complexes, dna antibodies and complement in patients with systemic lupus erythematosus: an analysis of their relationship to disease activity | Q52770506 | ||
| Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis. | Q52866849 | ||
| Value of anticardiolipin antibodies for monitoring disease activity in systemic lupus erythematosus and other rheumatic diseases. | Q52997075 | ||
| Detection of anti-DNA antibodies: a comparison between two Farr assays, Crithidia luciliae and a human chromosomal substrate assay. | Q53794432 | ||
| IgA anti-dsDNA antibodies in systemic lupus erythematosus: occurrence, incidence and association with clinical and laboratory variables of disease activity. | Q53853008 | ||
| The reactivity of sera from patients with systemic lupus erythematosus to seven different species of single and double stranded deoxyribonucleic acids. | Q53881341 | ||
| Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus | Q57351360 | ||
| Accuracy of Anticardiolipin Antibodies in Identifying a History of Thrombosis Among Patients With Systemic Lupus Erythematosus | Q57437612 | ||
| The C1q binding assay in systemic lupus erythematosus | Q57674775 | ||
| Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail | Q58161488 | ||
| Agalactosyl IgG and materno-fetal transmission of autoimmune neonatal lupus | Q58826884 | ||
| Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus | Q61628148 | ||
| Neuropsychiatric manifestations in patients with systemic lupus erythematosus: diagnostic and predictive value of longitudinal examination of anti-ribosomal P antibody | Q64389392 | ||
| Anti-DNA antibodies in the primary antiphospholipid syndrome (PAPS) | Q64389818 | ||
| Shifts of anti-Sm-specific antibodies in patients with systemic lupus erythematosus: Analysis by counter-immunoelectrophoresis, immunoblotting and RNA-immunoprecipitation | Q64390002 | ||
| Discrepancies between two procedures for ds-DNA antibody detection: Farr test and indirect immunofluorescence on Crithidia luciliae | Q64390284 | ||
| Anti-DNA antibodies of IgA class in patients with systemic lupus erythematosus | Q64390447 | ||
| Anti-DNA antibodies: the choice of assays for routine diagnostic work | Q64390517 | ||
| Specificity in systemic lupus erythematosus of antibodies to double-stranded DNA measured with the polyethylene glycol precipitation assay | Q64390675 | ||
| Clinical value of an integrated ELISA system for the detection of 6 autoantibodies (ssDNA, dsDNA, Sm, RNP/Sm, SSA, and SSB) | Q67280128 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | laboratory | Q483242 |
| diagnosis | Q16644043 | ||
| P304 | page(s) | 424-32 | |
| P577 | publication date | 2000-06-01 | |
| P1433 | published in | Journal of Clinical Pathology | Q6294965 |
| P1476 | title | The use of laboratory tests in the diagnosis of SLE | |
| P478 | volume | 53 |
| Q53117106 | A hypersensitive biotin-avidin-TRFIA for quantitative detection of ANA-Ig(GAM) and its clinical application. |
| Q52603256 | Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests. |
| Q35555256 | Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus |
| Q38637632 | Anti-DNA antibodies--quintessential biomarkers of SLE. |
| Q35552732 | Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis |
| Q35553340 | Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases |
| Q51767689 | Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders. |
| Q39508836 | Antibodies to an epitope from the Cha human autoantigen are markers of Chagas' disease. |
| Q37327182 | Antinuclear antibodies in rosacea patients |
| Q39012945 | Approach to the Management of Autoimmunity in Primary Immunodeficiency. |
| Q55113458 | Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus. |
| Q34249566 | Autoantibodies associated with rheumatic diseases |
| Q36570675 | Autoantibody determination in the diagnosis of systemic lupus erythematosus |
| Q47665041 | Autoimmune potential of perchloroethylene: Role of lipid-derived aldehydes |
| Q30245322 | Autoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management. |
| Q36527598 | Autoimmunity to isomerized histone H2B in systemic lupus erythematosus |
| Q42107384 | Automated Evaluation of Crithidia luciliae Based Indirect Immunofluorescence Tests: A Novel Application of the EUROPattern-Suite Technology |
| Q35729131 | Autoreactivity in human IgG+ memory B cells |
| Q34276645 | Belimumab and the clinical data |
| Q36277546 | Chorea as the first and only manifestation of systemic lupus erythematosus |
| Q26767511 | Clearance Deficiency and Cell Death Pathways: A Model for the Pathogenesis of SLE |
| Q47714722 | Clinical evaluation of cobas core anti-dsDNA EIA quant. |
| Q35446922 | Clinical performance evaluation of a novel, automated chemiluminescent immunoassay, QUANTA Flash CTD Screen Plus |
| Q35625532 | Comparison and evaluation of different methodologies and tests for detection of anti-dsDNA antibodies on 889 Slovenian patients' and blood donors' sera |
| Q45141928 | Comprehensive analysis of transcription factor expression patterns in peripheral blood mononuclear cell of systemic lupus erythematosus. |
| Q33391961 | Current practices in antinuclear antibody testing: results from the Belgian External Quality Assessment Scheme |
| Q30309818 | Cutaneous lupus erythematosus: a review |
| Q26782454 | Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus Erythematosus |
| Q92325030 | Detection of Anti-Extractable Nuclear Antigens in Patients with Systemic Rheumatic Disease via Fluorescence Enzyme Immunoassay and Its Clinical Utility |
| Q36560773 | Detection of antibodies to dsDNA: an overview of laboratory assays |
| Q62658324 | Determination of cut-off titers and agreement between immunofluorescence and immunoblotting methods for detecting antinuclear antibodies in children |
| Q45898976 | Differences between clinical and laboratory findings in patients with recent diagnosis of SLE according to the positivity of anti-dsDNA by the Crithidia luciliae method. |
| Q41773764 | Differential immunoglobulin class-mediated responses to components of the U1 small nuclear ribonucleoprotein particle in systemic lupus erythematosus and mixed connective tissue disease |
| Q33691818 | Differential oxidative modification of proteins in MRL+/+ and MRL/lpr mice: Increased formation of lipid peroxidation-derived aldehyde-protein adducts may contribute to accelerated onset of autoimmune response |
| Q35518822 | Differential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells |
| Q64935567 | Dihydropyridine Fluorophores Allow for Specific Detection of Human Antibodies in Serum. |
| Q34209141 | Disease association, origin, and clinical relevance of autoantibodies to the glycolytic enzyme enolase |
| Q38497471 | Efficiency of a solid-phase chemiluminescence immunoassay for detection of antinuclear and cytoplasmic autoantibodies compared with gold standard immunoprecipitation |
| Q36459907 | Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning |
| Q43011317 | Electronic publishing and internet learning |
| Q37470785 | Escaping from rejection |
| Q40621218 | Essential Requirement for IFN Regulatory Factor 7 in Autoantibody Production but Not Development of Nephritis in Murine Lupus. |
| Q39431992 | Evaluation of a high avidity anti-dsDNA IgG enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus |
| Q78307170 | Evaluation of a new automated enzyme fluoroimmunoassay using recombinant plasmid dsDNA for the detection of anti-dsDNA antibodies in SLE |
| Q30801548 | Evaluation of antinuclear antibodies by indirect immunofluorescence and line immunoassay methods': four years' data from Turkey |
| Q58735957 | Evidence of a distinct group of Black African patients with systemic lupus erythematosus |
| Q42625867 | IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus |
| Q51260044 | Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. |
| Q31151662 | Impact of external quality assessment on antinuclear antibody detection performance |
| Q92073068 | Interferon-induced protein 44-like gene promoter is differentially methylated in peripheral blood mononuclear cells of systemic lupus erythematosus patients |
| Q35150998 | Interpretation of ANA indirect immunofluorescence test outside the darkroom using NOVA view compared to manual microscopy |
| Q46926946 | Involvement of lipid peroxidation-derived aldehyde-protein adducts in autoimmunity mediated by trichloroethene |
| Q63214382 | Is there a predisposition for the development of autoimmune diseases in patients with fibromyalgia? Retrospective analysis with long term follow-up |
| Q58985221 | Linee guida per l’utilizzo dei test autoanticorpali nella diagnosi e nel monitoraggio delle malattie autoimmuni reumatiche sistemiche. Revisione 2015 |
| Q36737666 | Lipid peroxidation-derived aldehyde-protein adducts contribute to trichloroethene-mediated autoimmunity via activation of CD4+ T cells |
| Q98290673 | Long Non-Coding RNAs as New Biomarkers in Lupus Nephritis: A Connection Between Present and Future |
| Q46177271 | Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. |
| Q51513310 | Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases. |
| Q33675200 | N-Acetylcysteine protects against trichloroethene-mediated autoimmunity by attenuating oxidative stress |
| Q45047946 | New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA. |
| Q31162430 | Nitrosative stress and nitrated proteins in trichloroethene-mediated autoimmunity |
| Q38225438 | Optimizing pharmacotherapy of systemic lupus erythematosus: the pharmacist role |
| Q35933377 | Oxidative and nitrosative stress in trichloroethene-mediated autoimmune response |
| Q41573507 | Persistence of Epstein-Barr virus in self-reactive memory B cells |
| Q51039778 | Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. |
| Q57253775 | Proceedings of the 10th Asian Pacific Congress of Clinical Biochemistry in conjunction with the Australasian Association of Clinical Biochemists' 42nd Annual Scientific Conference |
| Q35690549 | Protein adducts of malondialdehyde and 4-hydroxynonenal contribute to trichloroethene-mediated autoimmunity via activating Th17 cells: dose- and time-response studies in female MRL+/+ mice |
| Q51926483 | Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. |
| Q36727307 | Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors |
| Q44234667 | Relationship between autoantibody clustering and clinical subsets in SLE: cluster and association analyses in Hong Kong Chinese |
| Q34654954 | Renal involvement in autoimmune connective tissue diseases |
| Q51372460 | Renal-limited 'lupus-like' nephritis. |
| Q83163076 | Retrospective analysis on the impact of tuberculosis on patients with systemic lupus erythematosus (SLE) |
| Q59102177 | Role of the clinical immunology laboratory in disease monitoring |
| Q47139886 | SLE and Serum Complement: Causative, Concomitant or Coincidental? |
| Q37258447 | Scavenging nucleic acid debris to combat autoimmunity and infectious disease |
| Q36410149 | Self-antigen recognition by follicular lymphoma B-cell receptors |
| Q50875976 | Serum metabolomic profiling in patients with systemic lupus erythematosus by GC/MS. |
| Q55347406 | Sialylated Autoantigen-Reactive IgG Antibodies Attenuate Disease Development in Autoimmune Mouse Models of Lupus Nephritis and Rheumatoid Arthritis. |
| Q36019008 | Single-cell antibody nanowells: a novel technology in detecting anti-SSA/Ro60- and anti-SSB/La autoantibody-producing cells in peripheral blood of rheumatic disease patients |
| Q84355517 | Study on clinical features and complications with systemic lupus erythematosus (SLE) activity in Chinese Han population |
| Q37360080 | Synthetic oligonucleotide antigens modified with locked nucleic acids detect disease specific antibodies |
| Q89919135 | Systemic lupus erythematosus |
| Q36987373 | Systemic lupus erythematosus: diagnosis for the non-specialist |
| Q37123859 | T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. |
| Q37995556 | TLR7 and TLR9 in SLE: when sensing self goes wrong |
| Q39561761 | The burden of the variability introduced by the HEp-2 assay kit and the CAD system in ANA indirect immunofluorescence test |
| Q36373315 | The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications |
| Q88801489 | The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease |
| Q37778654 | The impact of the EUSCLE core set questionnaire for the assessment of cutaneous lupus erythematosus |
| Q34078426 | The relationship between antinuclear antibody data and antibodies against extractable nuclear antigens in a large laboratory cohort |
| Q36870048 | Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation |
| Q51075145 | Toll-like receptor 8 deletion accelerates autoimmunity in a mouse model of lupus through a Toll-like receptor 7-dependent mechanism. |
| Q36403146 | Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus |
| Q35848152 | Toll-like receptors: potential targets for lupus treatment |
| Q41228881 | Translating epigenetics into clinic: focus on lupus |
| Q61450531 | Value of combined detection of anti-nuclear antibody, anti-double-stranded DNA antibody and C3, C4 complements in the clinical diagnosis of systemic lupus erythematosus |
| Q36583806 | Vitamin d deficiency in patients with systemic lupus erythematosus |
| Q84600271 | [Clinical utility of specialized immunologic testing in rheumatology in a secondary level hospital in Mexico] |
| Q81575727 | [Early diagnosis in patients with systemic lupus erythematosus (SLE)] |
| Q36386284 | iNOS null MRL+/+ mice show attenuation of trichloroethene-mediated autoimmunity: contribution of reactive nitrogen species and lipid-derived reactive aldehydes |
Search more.